Vial has raised $101.0M in total across 2 funding rounds.
Vial's investors include 20VC, Rexhep Dollaku, Blockchain Capital, Buckley Ventures, CRV, Data Tech Fund, Matt Ocko, DX Ventures, Founders Fund, General Catalyst, Gradient Ventures, Index Ventures.
Vial is a next-generation pharma company that builds a hyper-scalable drug development platform combining computationally designed therapeutics—such as biologics and RNA modalities—with automated clinical trials to drastically reduce costs and timelines.[1][2][4][6] It serves pharmaceutical sponsors and patients in areas of unmet need like obesity, atopic dermatitis, asthma, and inflammatory bowel disease, solving the core problem of inefficient, expensive drug discovery and trials through its TrialOS software for site startup, digital visit capture, and study analytics, alongside a computational discovery engine.[2][4][5] Vial has demonstrated strong growth momentum, raising over $100M from investors like General Catalyst and Box Group, receiving 41 RFP submissions last quarter, and advancing a pipeline with Phase 1 initiations planned for H2 2025.[2][6]
Vial was co-founded by Simon Burns (CEO, former tech product manager), with key executives including Chief Business Officer Max James and CFO Samir Meghji.[3][6] The idea emerged from analyzing clinical trials from first principles, identifying massive inefficiencies in cost, speed, and quality; as tech outsiders (including a Thiel Fellow), they built TrialOS to reimagine contract research organization (CRO) operations like a software company, emphasizing rapid iteration.[2][5] Early traction came from competing on cheaper, faster trials, leading to their "Act II": Battery Bio, where they launched in-house automated labs for chemical synthesis after being shocked by CDMO pricing, evolving into a vertically integrated drug factory.[2] Pivotal moments include mapping the entire trial process to software features and expanding to develop their own pipeline.[2][4]
Vial rides the wave of AI-driven drug discovery and automated biotech infrastructure, timing perfectly with surging demand for faster, cheaper trials amid rising obesity and chronic disease burdens.[1][2][4] Market forces like outdated CDMOs and trial costs (often 90% of drug development budgets) favor their model, introducing competitive pressure to stagnant sectors untouched for decades.[2] By vertically integrating discovery to trials, Vial influences the ecosystem as a "modern drug factory," potentially lowering barriers for sponsors, accelerating pipelines (e.g., multiple Phase 1 starts in 2025-2026), and inspiring tech-biotech hybrids like Benchling or Ro.[2][3][4]
Vial's trajectory points to dominance in scalable pharma, with near-term Phase 1 readouts for INHBE siRNA (obesity, H2 2025) and preclinical assets like Myostatin and IL-13 x TSLP advancing rapidly.[4] Trends like AI computation, RNA therapeutics, and precision trials will propel them, potentially expanding Battery Bio successes into a full pipeline while scaling CRO revenue. Their influence could evolve from disruptor CRO to pharma powerhouse, vertically owning high-value drugs and redefining efficiency—cementing the shift from legacy models to hyper-scalable biotech.[2][4][6]
Vial has raised $101.0M across 2 funding rounds. Most recently, it raised $34.0M Series A in November 2022.
